Cryo-Cell InternationalSTU:ZCY 58 Pretax Margin % is 0.91% as of Feb. 2026, which is 91% below its 10-year median of 9.85. GuruFocus rates STU:ZCY with a GF Score™ of 58/100 and a GF Value™ of €4.77 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 75.3% on this metric.
The historical rank and industry rank for Cryo-Cell International's Pretax Margin % or its related term are showing as below:
STU:ZCY'
s Pretax Margin % Range Over the Past 10 Years
Min: -42.64 Med: 9.85 Max: 16.18
Current: -8.96
STU:ZCY's Pretax Margin % is ranked worse than 75.3% of 664
companies
in the Healthcare Providers & Services industry
Industry Median: 4.01
vs STU:ZCY: -8.96
Cryo-Cell International (STU:ZCY) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Cryo-Cell International Pretax Margin % Related Terms
Cryo-Cell International Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZCY vs CCM, CDIX, EHSI: Pretax Margin % Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Pretax Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International (STU:ZCY) has a Pretax Margin % of 0.91% as of Feb. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cryo-Cell International and its competitors. This is 91% below median its historical median of 9.85. According to the industry distribution chart, Cryo-Cell International ranks #500 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 75.3%.
Is Cryo-Cell International's Pretax Margin % too high?
Cryo-Cell International's current Pretax Margin % of 0.91% is 91% below median its 10-year median of 9.85. The Healthcare Providers & Services industry median Pretax Margin % is 4.01. Cryo-Cell International's value of 0.91% is 77.3% below this industry median. Based on the distribution chart, Cryo-Cell International ranks #500 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Pretax Margin % compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #500 out of 664 companies for Pretax Margin %. This places Cryo-Cell International in the lower half of its industry. The industry median Pretax Margin % is 4.01. Cryo-Cell International's value of 0.91% is 77.3% below this benchmark. While the company's 10-year median is 9.85 vs. the industry median of 4.01, Cryo-Cell International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Healthcare Providers & Services company?
The median Pretax Margin % among Healthcare Providers & Services companies is 4.01, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryo-Cell International's current Pretax Margin % of 0.91% is 77.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Pretax Margin % is 4.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Pretax Margin % is 0.91%, which is 91% below median its own 10-year median of 9.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (STU:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.77, compared to a current price of €3.02 — trading 36.7% below its estimated fair value. The current Pretax Margin % is 0.91%, which is 91% below median its 10-year median of 9.85 and 77.3% below the Healthcare Providers & Services industry median of 4.01. Cryo-Cell International's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cryo-Cell International (STU:ZCY), the current Pretax Margin % is 0.91% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (STU:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €3.02 is trading 36.7% below its estimated GF Value™ of €4.77.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for STU:ZCY:
Pretax Margin %: 0.91% (91% below median its 10-year median of 9.85)
GF Value™: €4.77 vs. price of €3.02 (36.7% below fair value)
Industry Position: 77.3% below the Healthcare Providers & Services median (#500 of 664)
No single metric tells the full story. See the STU:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score
Get the complete analysis for STU:ZCY
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZCY has been successfully added to your 
